← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #830 OF 1,000 MOST-CITED

Quality control master manufacturing record; material review, disposition

FDA cited this observation 18 times across 17 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Foods18
BY FISCAL YEAR
FY20261
FY20253
FY20242
FY20223
FY20202
FY20192
FY20182
FY20173

How FDA worded it — real examples

Your quality control personnel did not conduct a material review and make a disposition decision when a batch deviated from the master manufacturing record.

Mytosynth Nutraceuticals, LLC · Jordan, Minnesota · Foods · 2026-05-07

Your quality control personnel did not conduct a material review and make a disposition decision when a batch deviated from the master manufacturing record.

Rowe Casa Organics · New Boston, Texas · Foods · 2025-09-19

Your quality control personnel did not conduct a material review and make a disposition decision when a batch deviated from the master manufacturing record.

Vitabest Nutrition, Inc. dba Vit-Best Nutrition · Tustin, California · Foods · 2025-07-18

Your quality control personnel did not conduct a material review and make a disposition decision when a batch deviated from the master manufacturing record.

Herbs America, Inc. · Grants Pass, Oregon · Foods · 2025-05-19

Your quality control personnel did not conduct a material review and make a disposition decision when a batch deviated from the master manufacturing record.

Bighorn Botanicals Inc · Noxon, Montana · Foods · 2024-08-30

Your quality control personnel did not conduct a material review and make a disposition decision when a batch deviated from the master manufacturing record.

Far East Summit LLC · Dexter, Oregon · Foods · 2024-02-14

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Food industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →